Hantz Financial Services Inc. Sells 5,965 Shares of Penumbra, Inc. $PEN

Hantz Financial Services Inc. cut its stake in Penumbra, Inc. (NYSE:PEN – Free Report) by 16.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 31,145 shares of the company’s stock after selling 5,965 shares during the period. Hantz Financial Services Inc.’s holdings in Penumbra were worth $9,683,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of PEN. Larson Financial Group LLC grew its position in shares of Penumbra by 4,100.0% during the 4th quarter. Larson Financial Group LLC now owns 84 shares of the company’s stock worth $26,000 after buying an additional 82 shares during the period. Morse Asset Management Inc acquired a new stake in shares of Penumbra during the 4th quarter worth approximately $39,000. Rothschild Investment LLC acquired a new stake in shares of Penumbra during the 3rd quarter worth approximately $40,000. Covestor Ltd grew its position in shares of Penumbra by 53.0% during the 3rd quarter. Covestor Ltd now owns 179 shares of the company’s stock worth $46,000 after buying an additional 62 shares during the period. Finally, Farther Finance Advisors LLC grew its position in shares of Penumbra by 27.1% during the 4th quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock worth $55,000 after buying an additional 38 shares during the period. Institutional investors and hedge funds own 88.88% of the company’s stock.

Get Penumbra alerts:

Penumbra Trading Down 0.1%

PEN opened at $328.46 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.02 and a quick ratio of 3.95. Penumbra, Inc. has a fifty-two week low of $221.26 and a fifty-two week high of $362.41. The firm has a market capitalization of $12.92 billion, a PE ratio of 75.68, a P/E/G ratio of 2.01 and a beta of 0.74. The company’s 50-day moving average is $329.87 and its 200 day moving average is $322.45.

Penumbra (NYSE:PEN – Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported $0.82 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.24). Penumbra had a return on equity of 10.87% and a net margin of 11.76%.The business had revenue of $374.76 million during the quarter, compared to analyst estimates of $370.47 million. During the same quarter in the prior year, the company earned $0.83 EPS. The company’s revenue was up 15.6% on a year-over-year basis. As a group, research analysts predict that Penumbra, Inc. will post 5.08 earnings per share for the current fiscal year.

Insider Transactions at Penumbra

In related news, CFO Maggie Yuen sold 2,432 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $342.30, for a total value of $832,473.60. Following the sale, the chief financial officer owned 18,353 shares in the company, valued at $6,282,231.90. This represents a 11.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Harpreet Grewal sold 100 shares of the company’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $328.22, for a total transaction of $32,822.00. Following the completion of the sale, the director owned 8,719 shares in the company, valued at $2,861,750.18. This represents a 1.13% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.90% of the company’s stock.

Analyst Ratings Changes

PEN has been the subject of several recent analyst reports. UBS Group reaffirmed a “neutral” rating and set a $374.00 price objective on shares of Penumbra in a research report on Thursday, February 26th. Evercore reaffirmed an “outperform” rating and set a $335.00 price objective on shares of Penumbra in a research report on Thursday, May 7th. Citigroup reduced their price objective on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a research report on Thursday, May 7th. Finally, Wall Street Zen raised shares of Penumbra to a “hold” rating in a research report on Saturday, May 9th. Three research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $361.33.

View Our Latest Report on PEN

Penumbra Company Profile

(Free Report)

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.

Featured Stories

• Five stocks we like better than Penumbra
• The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind
• 3 Rare Earth Stocks That Win No Matter What China Does Next
• Amylyx Stock: Why the Full Pipeline Story Matters
• Palantir and Dell Build an AI OS for the Paranoid

Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra, Inc. (NYSE:PEN – Free Report).

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.